

## CURRICULUM VITAE

### Helen Giza

Member of the Management Board of Fresenius Management SE  
Business segment Fresenius Medical Care

Member of the Management Board since December 6, 2022; term expires in 2027

Born: 1968  
Place of birth: Church Village, Great Britain  
Nationality: British / American

#### Professional Experience

- since 12/2022 Fresenius Group  
Member of the Management Board of Fresenius Management SE  
responsible for the business segment Fresenius Medical Care
- 2019 – present Fresenius Medical Care Management AG  
Persönlich haftende Gesellschafterin der Fresenius Medical Care AG & Co. KGaA
- ▶ since 12/2022 Chief Executive Officer and acting Chief Financial Officer
  - ▶ since 2021 Chief Transformation Officer
  - ▶ since 2019 Chief Financial Officer
- 2008– 2019 Takeda Pharmaceutical Company Limited
- ▶ 2018 – 2019 Chief Integration & Divestiture Management Officer
  - ▶ 2015 – 2018 Senior Vice President, Chief Financial Officer – U.S. Business Unit
  - ▶ 2008 – 2015 Vice President, Finanzvorstand - US Business Unit
- 2004 – 2008 TAP Pharmaceutical Products Inc.
- ▶ 2005 – 2008 Vice President & Division Controller
  - ▶ 2004 – 2005 Assistant Controller
- 1999 – 2004 Abbott Laboratories
- ▶ 2003 – 2004 Area Controller Commercial – Asia Pacific Region
  - ▶ 1999 – 2003 Finance Manager – Manufacturing Operations
- 1996 – 1999 Dana Incorporated
- ▶ 1996 – 1999 Finance Director
- 1991 – 1996 ITT, Inc
- ▶ 1991 – 1996 Cost Accountant

#### Education

Chartered Certified Accountant, Great Britain  
Master of Business Administration  
Kellogg School of Management, Northwestern University, Evanston, Illinois

#### Membership of comparable German or foreign supervisory bodies

Vifor Fresenius Medical Care Renal Pharma Ltd., Switzerland (Fresenius Group mandate)